Lifestyle Asset Management Inc. Sells 813 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Lifestyle Asset Management Inc. reduced its position in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 5.3% during the 1st quarter, HoldingsChannel.com reports. The fund owned 14,419 shares of the company’s stock after selling 813 shares during the quarter. Lifestyle Asset Management Inc.’s holdings in Dr. Reddy’s Laboratories were worth $1,058,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in RDY. Desjardins Global Asset Management Inc. lifted its position in Dr. Reddy’s Laboratories by 7.2% during the fourth quarter. Desjardins Global Asset Management Inc. now owns 3,786 shares of the company’s stock worth $263,000 after purchasing an additional 255 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Dr. Reddy’s Laboratories by 54.7% in the first quarter. GAMMA Investing LLC now owns 721 shares of the company’s stock worth $53,000 after acquiring an additional 255 shares during the last quarter. Schonfeld Strategic Advisors LLC lifted its holdings in shares of Dr. Reddy’s Laboratories by 1.5% in the third quarter. Schonfeld Strategic Advisors LLC now owns 20,200 shares of the company’s stock worth $1,351,000 after acquiring an additional 300 shares during the last quarter. PDS Planning Inc lifted its holdings in shares of Dr. Reddy’s Laboratories by 6.3% in the fourth quarter. PDS Planning Inc now owns 5,239 shares of the company’s stock worth $365,000 after acquiring an additional 309 shares during the last quarter. Finally, Parallel Advisors LLC lifted its holdings in shares of Dr. Reddy’s Laboratories by 6.1% in the fourth quarter. Parallel Advisors LLC now owns 6,514 shares of the company’s stock worth $453,000 after acquiring an additional 377 shares during the last quarter. 14.02% of the stock is owned by institutional investors.

Analysts Set New Price Targets

RDY has been the subject of a number of research reports. Barclays increased their target price on shares of Dr. Reddy’s Laboratories from $80.00 to $81.00 and gave the stock an “overweight” rating in a report on Wednesday, May 8th. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 16th.

Dr. Reddy’s Laboratories Trading Down 0.1 %

NYSE RDY traded down $0.07 during trading hours on Wednesday, reaching $76.05. The company’s stock had a trading volume of 104,726 shares, compared to its average volume of 222,696. The firm has a fifty day simple moving average of $71.62 and a 200-day simple moving average of $72.05. The stock has a market cap of $12.69 billion, a P/E ratio of 18.87, a P/E/G ratio of 1.71 and a beta of 0.55. Dr. Reddy’s Laboratories Limited has a 52 week low of $61.60 and a 52 week high of $77.72. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.58 and a quick ratio of 1.92.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its earnings results on Tuesday, May 7th. The company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.86 by $0.08. The business had revenue of $850.00 million during the quarter, compared to the consensus estimate of $825.20 million. Dr. Reddy’s Laboratories had a net margin of 19.97% and a return on equity of 21.32%. Equities analysts forecast that Dr. Reddy’s Laboratories Limited will post 4.03 earnings per share for the current fiscal year.

Dr. Reddy’s Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.